Stem Cells http://www.stemcellsportal.com/
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bensinger, W. I.
Right arrow Articles by Buckner, C. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bensinger, W. I.
Right arrow Articles by Buckner, C. D.
Stem Cells, Vol. 14, No. 1, 90-105, January 1996
© 1996 AlphaMed Press

CONCISE REVIEW

Transplantation of Allogeneic Peripheral Blood Stem Cells Mobilized by Recombinant Human Granulocyte Colony Stimulating Factor

William I. Bensinger, Reginald A. Clift, Claudio Anasetti, Frederick A. Appelbaum, Taner Demirer, Scott Rowley, Brenda M. Sandmaier, Beverly Torok-Storb, Rainer Storb, C. Dean Buckner

The Fred Hutchinson Cancer Research Center, Seattle, Washington, USA; the Department of Medicine of the University of Washington, Seattle, Washington, USA

Key Words. Allogeneic • Transplantation • Peripheral blood stem cells

Dr. William I. Bensinger, Fred Hutchinson Cancer Research Center, 1124 Columbia Street, Seattle, WA 98104-2092, USA.

Recombinant G-CSF has been given to over 150 normal donors for the collection of allogeneic or syngeneic peripheral blood stem cells (PBSC). G-CSF was found to be well-tolerated with mild-moderate bone pain, edema and mild thrombocytopenia being the observed side effects. To date, approximately 90 unmodified primary PBSC transplants from HLA-identical related donors have been performed with engraftment that is, in general, considerably more rapid than marrow. Acute graft-versus-host-disease (GVHD), grades II-IV occurred in 47% of patients and grades III-IV in 17%. Despite the infusion of one to two logs more T cells, these results are not remarkably different than would be expected with marrow transplantation. There have also been successful reports of using G-CSF mobilized allogeneic PBSC following second transplants for graft rejection or relapse. Allogeneic PBSC have been infused without reconditioning for correction of graft failure and unmodified or CD34 selected PBSC have also been given with marrow to augment the dose of hematopoietic cells. Further studies are needed to define the role of allogeneic PBSC for transplantation, refine PBSC mobilization and collection techniques and to evaluate the long-term effects of cytokines in normal donors.




This article has been cited by other articles:


Home page
 CirculationHome page
H. Ince, M. Petzsch, H. D. Kleine, H. Schmidt, T. Rehders, T. Korber, C. Schumichen, M. Freund, and C. A. Nienaber
Preservation From Left Ventricular Remodeling by Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Use of Granulocyte-Colony-Stimulating Factor (FIRSTLINE-AMI)
Circulation, November 15, 2005; 112(20): 3097 - 3106.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Crough, M. Nieda, and A. J. Nicol
Granulocyte Colony-Stimulating Factor Modulates {alpha}-Galactosylceramide-Responsive Human V{alpha}24+V{beta}11+ NKT Cells
J. Immunol., October 15, 2004; 173(8): 4960 - 4966.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. S. Forrester, M. J. Price, and R. R. Makkar
Stem Cell Repair of Infarcted Myocardium: An Overview for Clinicians
Circulation, September 2, 2003; 108(9): 1139 - 1145.
[Full Text] [PDF]

Home page
 BloodHome page
S. S. Joshi, J. C. Lynch, S. Z. Pavletic, S. R. Tarantolo, S. J. Pirruccello, A. Kessinger, and M. R. Bishop
Decreased immune functions of blood cells following mobilization with granulocyte colony-stimulating factor: association with donor characteristics
Blood, September 15, 2001; 98(6): 1963 - 1970.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
J. Banchereau, B. Pulendran, R. Steinman, and K. Palucka
Will the Making of Plasmacytoid Dendritic Cells In Vitro Help Unravel Their Mysteries?
J. Exp. Med., December 18, 2000; 192(12): F39 - F44.
[Full Text] [PDF]

Home page
 BloodHome page
Y.-J. Liu and B. Blom
Introduction: TH2-inducing DC2 for immunotherapy
Blood, April 15, 2000; 95(8): 2482 - 2483.
[Full Text] [PDF]

Home page
 BloodHome page
M. Arpinati, C. L. Green, S. Heimfeld, J. E. Heuser, and C. Anasetti
Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells
Blood, April 15, 2000; 95(8): 2484 - 2490.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. M. Sloand, S. Kim, J. P. Maciejewski, F. Van Rhee, A. Chaudhuri, J. Barrett, and N. S. Young
Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo
Blood, April 1, 2000; 95(7): 2269 - 2274.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Engelhardt, H. Bertz, M. Afting, C. F. Waller, and J. Finke
High- Versus Standard-Dose Filgrastim (rhG-CSF) for Mobilization of Peripheral-Blood Progenitor Cells From Allogeneic Donors and CD34+ Immunoselection
J. Clin. Oncol., July 1, 1999; 17(7): 2160 - 2160.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
J. Ferrara, K. Cooke, L Pan, and W Krenger
The immunopathophysiology of acute graft-versus-host-disease
Stem Cells, September 1, 1996; 14(5): 473 - 489.
[Abstract]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS
http://www.peprotech.com/
Copyright © 1996 by AlphaMed Press.